Vilobelimab
Vilobelimab is a monoclonal antibody that targets and inhibits the activity of complement component 5a (C5a), a protein involved in the inflammatory response. It is being investigated for its potential therapeutic applications in various inflammatory and autoimmune diseases.
Mechanism of Action[edit | edit source]
Vilobelimab works by binding to C5a, a potent inflammatory mediator that is part of the complement system. The complement system is a component of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens and damaged cells. By inhibiting C5a, vilobelimab reduces inflammation and tissue damage associated with excessive complement activation.
Therapeutic Applications[edit | edit source]
Vilobelimab is being studied for its potential use in treating several conditions, including:
Sepsis[edit | edit source]
Sepsis is a life-threatening condition caused by the body's response to an infection. Vilobelimab is being investigated for its ability to reduce the excessive inflammatory response seen in sepsis, which can lead to organ failure and death.
COVID-19[edit | edit source]
During the COVID-19 pandemic, vilobelimab has been studied for its potential to mitigate the severe inflammatory response known as a cytokine storm, which can occur in severe cases of COVID-19.
Hidradenitis Suppurativa[edit | edit source]
Hidradenitis suppurativa is a chronic skin condition characterized by painful lumps under the skin. Vilobelimab is being evaluated for its efficacy in reducing the inflammation and lesions associated with this condition.
ANCA-associated Vasculitis[edit | edit source]
ANCA-associated vasculitis is a group of diseases characterized by inflammation of blood vessels. Vilobelimab is being researched for its potential to reduce the inflammation and prevent damage to blood vessels in these conditions.
Clinical Trials[edit | edit source]
Vilobelimab is currently undergoing various stages of clinical trials to evaluate its safety and efficacy in the aforementioned conditions. These trials are essential for determining the appropriate dosages, potential side effects, and overall effectiveness of the drug.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
